Related Experiment Video
Updated: Aug 9, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
[Multifocal motor neuropathy with persistent conduction blocks. A chronic immune-mediated neuropathy]
Jean-Marc Léger1, Steven Vargas
1Centre de Référence Maladies Neuromusculaires Rares, CHU Pitié-Salpêtrière, Paris. jean-marc.leger@psl.aphp-paris.fr
Presse Medicale (Paris, France : 1983)
|April 15, 2006
Summary
Multifocal motor neuropathy (MMN) is a rare condition affecting motor nerves. High-dose intravenous immunoglobulin therapy offers short-term benefits for most patients with MMN.
Area of Science:
- Neurology
- Immunology
Background:
- Multifocal motor neuropathy (MMN) is a distinct neurological disorder characterized by conduction blocks exclusively in motor nerves.
- It typically presents as an asymmetric, chronic, and relapsing condition, predominantly affecting the upper limbs of men over 50.
Purpose of the Study:
- To summarize the clinical characteristics, diagnostic criteria, and treatment outcomes of multifocal motor neuropathy.
- To evaluate the efficacy and limitations of current therapeutic strategies for MMN.
Main Methods:
- Review of clinical presentations and diagnostic hallmarks of MMN.
- Analysis of treatment responses to intravenous polyvalent immunoglobulins (IVIg), corticosteroids, and plasma exchange.
Main Results:
- MMN is defined by motor nerve conduction blocks; 40-50% of patients have anti-GM1 IgM antibodies.
- Short-term treatment with high-dose IVIg is effective in 70-80% of MMN cases.
- Corticosteroids and plasma exchange are generally ineffective and may worsen the condition.
Conclusions:
- High-dose IVIg provides significant short-term relief for multifocal motor neuropathy.
- The long-term benefits of IVIg and the efficacy of other immunomodulatory treatments for MMN remain under investigation.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...